|
|||||
|
|
| 人组织型纤溶酶原激活剂(t-PA)突变体的研究现状及进展 | |
| 引用本文： | 江成英,郭宏文,冮洁.人组织型纤溶酶原激活剂(t-PA)突变体的研究现状及进展[J].农产品加工．学刊,2008(7). |
| 作者姓名： | 江成英 郭宏文 冮洁 |
| 作者单位： | 1. 齐齐哈尔大学生命科学与工程学院,黑龙江,齐齐哈尔,161006;齐齐哈尔大学黑龙江省普通高校农产品加工重点实验室,黑龙江,齐齐哈尔,161006 2. 齐齐哈尔大学生命科学与工程学院,黑龙江,齐齐哈尔,161006 3. 大连民族学院,生命科学学院,辽宁,大连,116600 |
| 摘 要： | 人组织型纤溶酶原激活剂(t-PA)是一种高效特异的溶血栓药物,但天然的t-PA存在半衰期短,有潜在的引起颅内出血的危险等缺点,因而限制了它的广泛应用。世界各国的科研人员利用了分子设计和基因工程等技术,构建了一系列的t-PA突变体,旨在提高对纤维蛋白的亲和力,延长半衰期,提高纤溶效率,减少颅内出血的危险。综述了t-PA的结构和功能、对t-PA结构的改造,以及一系列t-PA突变体的研究现状及进展情况。 |
| 关 键 词： | 溶栓剂 基因工程 t-PA突变体 表达 |
Advances and Actuality in the Studies of Human Tissue-type Plasminogen Activator (t-PA) Mutants |
|
| Jiang Chengying,Guo Hongwen,Gang Jie.Advances and Actuality in the Studies of Human Tissue-type Plasminogen Activator (t-PA) Mutants[J].Nongchanpin Jlagong.Xuekan,2008(7). | |
| Authors: | Jiang Chengying Guo Hongwen Gang Jie |
| Abstract: | Human tissue-type plasminogen activator(t-PA)is a medicine used in thrombolytic treatment efficiently. Its application was limited by its defects,such as short half life and leading to blood in skull. Scientists have constructed a series of t-PA mutants which improved the appetency with fibrin,prolonged its half life,increased the efficiency of fibrinolysis and reduce the danger of blood in skull by adopting molecule design and gene engineering technology. The subject introduces the structure and function o... |
| Keywords: | thrombolytic agents gene engineering t-PA mutant expression |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |